6 completed. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow Recurrent Medulloblastoma: new trials by email Literature Review of Recurrent Medulloblastoma trials Research Report on Recurrent Medulloblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Adavosertib, Irinotecan Hydrochloride - Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 76 | 2014-03-28 | 2023-09-26 |
| Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Bevacizumab, Irinotecan Hydrochloride, Temozolomide - Central Nervous System Neoplasm, Pineoblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 108 | 2010-11-22 | 2021-07-23 |
Medulloblastoma (6) · Central Nervous System Neoplasms (5) · Neuroblastoma (5) · Neuroectodermal Tumors, Primitive, Peripheral (5) · Rhabdomyosarcoma (5) · Ependymoma (4) · Glioma (4) · Hepatoblastoma (4) · Histiocytosis, Langerhans-Cell (4) · Lymphoma, Non-Hodgkin (4) · Osteosarcoma (4) · Rhabdoid Tumor (4) · Sarcoma (4) · Wilms Tumor (4) · Sarcoma, Ewing (3)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neoplasms, Neuroepithelial (6) · Neuroectodermal Tumors (6) · Myosarcoma (5) · Neoplasms, Connective and Soft Tissue (5) · Neoplasms, Muscle Tissue (5) · Nervous System Diseases (5) · Nervous System Neoplasms (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Female Urogenital Diseases (4)
Irinotecan (2) · Bevacizumab (1) · Disulfides (1) · Immunoglobulin G (1) · LY3023414 (1) · Magnetic Resonance Spectroscopy (1) · Phantoms, Imaging (1) · Specimen Handling (1) · Temozolomide (1) · X-Rays (1) · adavosertib (1) · olaparib (1) · palbociclib (1) · tazemetostat (1)
National Cancer Institute (NCI) (6)
United States (6) · Puerto Rico (5) · Canada (2) · Australia (1) · New Zealand (1)
Adam S Levy (1) · Julia Glade-Bender (1) · Kristina A Cole (1) · Rajen Mody (1) · Susan N Chi (1) · Theodore W Laetsch (1)
PMID 31401903, PMID 38815151, PMID 39298716
U10CA180886 (5), U10CA098543 (1), UM1CA097452 (1)